MTF, Aastrom form partnership to develop novel treatments for tissue regeneration.
Under terms of the alliance, the companies will provide each other with rights to their respective technologies for treatments and products that are based on combinations of MTF's matrices and Aastrom's Tissue Repair Cells (TRCs). The companies say they will share in the development and clinical trial expense of the treatment approaches and products, and will adopt a coordinated promotion and marketing strategy for future products. In addition to bone graft applications, the companies will explore new approaches for the regeneration of joint cartilage, as well as effective combinations of TRCs with MTF's new ceramic matrix technology.
The market for these applications is estimated at more than 1.4 million procedures annually, including spinal fusions, non-union fractures, dental defects and facial bone repair.
Contact: Tom Shaffer, MTF - (800) 946-9008, ext. 2522, or Kris Maly, Aastrom - (734) 930-5777. Web sites: www.mtf.org, and www.aastrom.com.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Musculoskeletal Transplant Foundation, Aastrom Biosciences Inc.|
|Article Type:||Brief Article|
|Date:||Jun 14, 2003|
|Previous Article:||Bionic eye can restore some sight to the blind.|
|Next Article:||FDA to allow Anamed to expand Phase II study of its PermaVision Intracorneal lens.|